Eloralintide for Obstructive Sleep Apnea

(ENLIGHTEN-3 Trial)

This trial tests a new treatment called eloralintide for individuals with moderate-to-severe obstructive sleep apnea (a sleep disorder where breathing repeatedly stops and starts) who are also overweight or obese. The researchers aim to determine if eloralintide is safe and effective for these individuals. Participants will be divided into two groups: those not using Positive Airway Pressure (PAP) therapy and those who have used PAP therapy for at least three months. This trial suits individuals who have tried and failed to lose weight through diet and have a confirmed diagnosis of sleep apnea. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. However, you cannot have taken any weight loss medications or remedies within 90 days before the screening.

Research has shown that eloralintide is generally well-tolerated. In earlier studies, participants reported only a few side effects, mostly mild ones like nausea or headaches, which usually resolved over time.

Eloralintide is also under study for potential use in treating obesity and sleep apnea. Other studies on similar treatments have found them safe for people with these conditions. Since this trial is in an advanced stage, earlier safety checks have shown promising results.

Most treatments for obstructive sleep apnea, like CPAP machines and oral appliances, work by physically keeping airways open during sleep. But Eloralintide offers a fresh approach by being delivered subcutaneously (under the skin) and potentially working internally to address the root cause of airway obstruction. This new method could make it easier for people who struggle with the bulkiness or discomfort of traditional devices. Researchers are excited because Eloralintide might provide a more convenient and less intrusive option, encouraging better patient adherence and effectiveness.

Research has shown that eloralintide may benefit people with moderate-to-severe obstructive sleep apnea, particularly those who are overweight or obese. Studies suggest that this drug might improve sleep apnea by reducing the frequency of breathing interruptions during sleep. Some early findings indicate that eloralintide can decrease sleep disruptions, leading to better sleep quality. Although detailed information on its effectiveness remains limited, these initial results offer hope. This trial will test eloralintide in different formulations, presenting a promising option for those who struggle with current treatments like Positive Airway Pressure (PAP) therapy.¹³⁴⁶⁷